Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults

• Published in: Nephrology, dialysis, transplantation Vol. 31; no. 1; pp. 95 - 103
• Main Authors: Derad, Inge, Obermann, Birgit, Katalinic, Alexander, Eisemann, Nora, Knobloch, Johannes K-M, Sayk, Friedhelm, Wellhöner, Peter, Lehnert, Hendrik, Solbach, Werner, Süfke, Sven, Steinhoff, Jürgen, Nitschke, Martin
• Format: Journal Article
• Language: English
• Published: England 01-01-2016
• Subjects: Adult; Anti-Bacterial Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Azithromycin - therapeutic use; Complement Inactivating Agents - therapeutic use; Drug Therapy, Combination; Enterohemorrhagic Escherichia coli; Escherichia coli Infections - complications; Escherichia coli Infections - drug therapy; Escherichia coli Infections - microbiology; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemolytic-Uremic Syndrome - complications; Hemolytic-Uremic Syndrome - drug therapy; Hemolytic-Uremic Syndrome - microbiology; Humans; Hypertension - microbiology; Hypertension - prevention & control; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic - microbiology; Renal Insufficiency, Chronic - prevention & control; Treatment Outcome; chronic kidney disease; proteinuria; HUS; epidemiology and outcome; kidney failure; STEC O104:H4; hypertension
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfv255

Shiga toxin-producing, enteroaggregative Escherichia coli was responsible for the 2011 outbreak of haemolytic uraemic syndrome (HUS). The present single-centre, observational study describes the 1-year course of the disease with an emphasis on kidney function. Outcome data after 1 year are associated with treatment and patient characteristics at onset of HUS.
Patients were treated according to a standardized approach of supportive care, including a limited number of plasmapheresis. On top of this treatment, patients with severe HUS (n = 35) received eculizumab, a humanized anti-C5 monoclonal antibody inhibiting terminal complement activation. The per-protocol decision--to start or omit an extended therapy with eculizumab accompanied by azithromycin--separated the patients into two groups and marked Day 0 of the prospective study. Standardized visits assessed the patients' well-being, kidney function, neurological symptoms, haematological changes and blood pressure.
Fifty-six patients were regularly seen during the follow-up. All patients had survived without end-stage renal disease. Young(er) age alleviated restoring kidney function after acute kidney injury even in severe HUS. After 1 year, kidney function was affected with proteinuria [26.7%; 95% confidence interval (CI) 13.8-39.6], increased serum creatinine (4.4%, CI 0.0-10.4), increased cystatin C (46.7%, CI 32.1-61.3) and reduced (<90 mL/min) estimated glomerular filtration rate (46.7%, CI 32.1-61.3). Nine of the 36 patients without previous hypertension developed de novo hypertension (25%, CI 10.9-39.1). All these patients had severe HUS.
Although shiga toxin-producing Escherichia coli (STEC)-HUS induced by O104:H4 was a life-threatening acute disease, follow-up showed a good recovery of organ function in all patients. Whereas kidney function recovered even after longer duration of dialysis, chronic hypertension developed after severe HUS with neurological symptoms and could not be prevented by the extended therapy.